Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study Journal Article
| Authors: | Gordan, L. N.; Tan, C. R.; Vescio, R.; Ye, J. C.; Schinke, C.; Medhekar, R.; Fu, A. Z.; Lafeuille, M. H.; Thompson-Leduc, P.; Khare, V.; Reitan, J.; Milkovich, G.; Kaila, S.; Davies, F.; Usmani, S. Z. |
| Article Title: | Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study |
| Abstract: | Background: Daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib, lenalidomide and dexamethasone (VRd) are preferred regimens for transplant ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). Both DRd and VRd demonstrated superior efficacy versus Rd in the MAIA and SWOG S0777 trials, respectively, but there is no head-to-head (H2H) clinical trial comparing their efficacy. Differing populations in the MAIA and S0777 trials make an unadjusted comparison of outcomes challenging and biased. The current TAURUS study is the first real-world H2H study comparing progression-free survival (PFS) among TIE NDMM patients treated with DRd or VRd as first-line (1L) in similar clinical settings. Materials and Methods: A multicenter chart review study was conducted at nine sites across the United States. All TIE patients treated with DRd and a randomly selected population of VRd patients were included. TIE NDMM patients aged ≥65 were included if they initiated 1L DRd/VRd between January 2019 and September 2021. PFS was defined as the time from DRd/VRd initiation until disease progression or death. A doubly-robust multivariable Cox regression model combined with inverse probability of treatment weighting (IPTW) methodology was used to compare PFS between cohorts. Results: Weighted cohorts comprised 91 DRd and 87 VRd patients. Thirteen DRd and 24 VRd patients experienced progression/death. Patients treated with DRd had a lower risk of progression/death versus VRd (adjusted hazard ratio: 0.35, 95% confidence interval: [0.17; 0.73]). Conclusion: DRd is associated with a significantly lower risk of disease progression or death compared to VRd as 1L treatment for TIE NDMM patients. © 2023 The Author(s) |
| Keywords: | cancer survival; controlled study; aged; major clinical study; lenalidomide; clinical trial; cancer combination chemotherapy; cancer patient; antineoplastic agent; progression free survival; bortezomib; multiple myeloma; antineoplastic combined chemotherapy protocols; cohort analysis; dexamethasone; medical record review; retrospective study; monoclonal antibody; antibodies, monoclonal; death; disease progression; multicenter study; antibodies; drug therapy; disease exacerbation; hematology; progression-free survival; clinical outcome; monoclonal; humans; human; male; female; article; daratumumab |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | 1 |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-01-01 |
| Start Page: | 55 |
| End Page: | 63 |
| Language: | English |
| DOI: | 10.1016/j.clml.2023.09.003 |
| PUBMED: | 37838502 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work